AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05370911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: The first oral dose will be 25 mg, and the second dose will be either 25 mg or 30 mg, depending on response to first dose.~Psilocybin is a naturally occurring hallucinogenic ingredient found in some varieties of mushrooms that can be produced synthetically. It is considered to be a serotonergic psychedelic. We will use synthetically produced oral psilocybin in this study.~Other Names:~Magic Mushrooms
Study NCT04870515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard lifestyle recommendations
Study NCT04870515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive dietary instructions
Study NCT04870515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete aerobic and strength/resistance exercises
Study NCT04870515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04870515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04870515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04870515 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06209138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 fluorouracil
Description: 5 fluorouracil (5FU) using different ratios of hydroxyl propyl methyl cellulose (HPMC) and Zein
Study NCT06209138 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Normal saline solution contains 0.9 percent sodium chloride (salt)
Study NCT05784350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluid boluses guided by IVC diameter via US/administration of pre-operative IV Odansetrone
Description: group A will undergo fluid repletion guided by their IVC-CI - if a collapsible IVC, defined as a CI equal or greater than 43%, is observed, patients will receive repeated Lactated Ringer's 500 ml boluses followed by repeated IVC-CI measurements until their CI is less than 43%, and up to 1.5L.~Group B will undergo the same intervention, with the addition of intravenous ondansetron 4 mg in 10 ml normal saline 20 minutes before induction of general anesthesia.
Study NCT05327465 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic and resistance exercise
Description: Perform exercise at home with virtual supervision, including aerobic exercise (e.g.,cycling), which can improve cardiovascular (heart) and lung function, and resistance exercise (e.g., dumbbell lifting and using resistance band. The exercises will be performed three times per week for 16 weeks, and virtually supervised by a professional exercise trainer
Study NCT05327465 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Maintenance of baseline exercise levels for 16 weeks with an offer to perform the same exercise (aerobic and resistance exercise) program after 16 weeks.
Study NCT05506449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP®
Description: Subjects randomized to the Treatment Arm will undergo Impella CP placement prior to PCI. Right heart catheterization will be performed prior to or immediately after PCI.~Use of IABP will not be allowed in the Treatment Arm.
Study NCT05506449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This may include inotropes and/or vasopressors. An IABP may or may not be used according to local practice and the specific condition of each individual patient. If an IABP is used, it may be placed prior to or after PCI, and its timing of explant is left to the discretion of the Investigator.
Study NCT06779019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: LSCI
Description: LSCI evaluates at 2 timings:immediately after the mastectomy (prior to immediate reconstruction) and again following reconstruction (after the skin was sutured). The perfusion score was calculated by normalizing these values against the perfusion value of a control.
Study NCT06779019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ICG (Indocyanine Green)
Description: Performed immediately after the mastectomy (prior to immediate reconstruction) .Perfusion scores were determined by comparing the fluorescence intensity of the target area to that of the non-surgical region on the contralateral chest wall.
Study NCT06777563 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief psychological counselling and health education
Description: This is a brief 1-on-1 psychological counselling, including potential mood fluctuation during pregnancy, possible prepartum depressive symptoms, and available psychiatric consultation and medication in Hong Kong with self-help psychoeducational materials.
Study NCT06423482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEK bar
Description: The framework will be constructed from Poly-Ether-Ether-Ketone (PEEK). The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
Study NCT06423482 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Titanium bar
Description: The framework will be constructed from titanium. The framework will be digitized by using a desktop scanner (Tabletop Scanner, Medit T-310; Medit Corp). The STL file produced will be considered as a reference file. Each framework will be scanned intraorally (n=10) by using an intraoral scanner (IOS) (Medit i700; Medit Corp).
Study NCT06777563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psychological counselling and health education
Description: This is a brief 1-on-1 psychological counselling, including potential mood fluctuation during pregnancy, possible prepartum depressive symptoms, and available psychiatric consultation and medication in Hong Kong with self-help psychoeducational materials.
Study NCT04910152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRD4 Inhibitor PLX51107
Description: Given PO
Study NCT05326451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with HD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down. Sessions will be remotely supervised by trained research staff (RA), and will run from Monday through Friday for four consecutive weeks.
Study NCT06491030 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Align PJK™ TLSO brace
Description: Patients will get randomized to receiving and wearing a back brace for 6 weeks postoperatively.
Study NCT06491030 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive the standard of care postoperative instructions without a brace
Study NCT04837222 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT05714683 — intervention group
Intervention type: DRUG
Intervention: Semaglutide
Description: All participants will be treated with oral semaglutide for 26 weeks according to routine clinical practice at the discretion of the treating physician according to the label approved by MFDS. The prescription of semaglutide will be separated from the decision to include the participant in the study.
Study NCT05854550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apreo Implant Group
Description: One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
Study NCT05222971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1,500 mg IV on Day 1~Every 4 weeks
Study NCT05222971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Olaparib 300 mg twice daily~Every 4 weeks
Study NCT05222971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg twice daily~Every 4 weeks
Study NCT05058287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depo-Medrol 40Mg/Ml Suspension for Injection
Description: 40mg Depo-Medrol mixed with hemostatic matrix
Study NCT05058287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mL of sterile normal saline mixed with hemostatic matrix
Study NCT05356104 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide extended release
Description: 2mg once weekly via subcutaneous injection
Study NCT05056844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast Enhanced Digital Mammography
Description: Undergo CESM
Study NCT05056844 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digital Tomosynthesis Mammography
Description: Undergo DBT
Study NCT06777563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 Weeks of Ecological Momentary Assessment (EMA)
Description: The 2-week EMA period will start the next day. Participants will be prompted to answer questions about emotion (e.g. worry, enjoyment, anxiety, etc.) and other lifestyle and environmental triggers through the smartphone notification function. There will be a 2-hour window for each assessment before expiration and total 5 assessments a day.
Study NCT06777563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 weeks of mobile health psychological support
Description: A total of 20 regular instant messages (e.g., via WhatsApp) personalised by baseline demographic characteristics (current pregnancy details, history of postpartum mental illness) and results of EMA will be sent to the participants in multi-media formats.
Study NCT06777563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-guided telephone counselling booster
Description: A 45-minute telephone counselling based on CBT.
Study NCT06269198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WARD-CSS
Description: Patients' continuously monitored vital signs will be recorded via a bedside tablet device (data not visible).~The clinical staff will have access to the continuously monitored vital signs through a mobile device (smart phone) with a purpose-built app-based GUI displaying vital sign status and summaries, alarms, and device connectivity. The GUI will alert the clinical staff (acoustic and visual signals) when any of the predefined thresholds for deviating vital signs are exceeded.
Study NCT05797246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg IV every three weeks for 3 cycles and then every 6 weeks for a total treatment course of 11 cycles for approximately 1 year total.
Study NCT05220332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart to Heart
Description: The Heart to Heart intervention will be delivered at the churches over 6 months. The intervention consists of 12 bible study sessions (45 minutes) led by the Senior Pastor and 24 behavior change small group sessions (90 minutes) led by a trained Rush staff interventionist. These sessions are open to the entire church membership and focus on improving diet and physical well being. A community health worker will provide individualized support to participants with uncontrolled blood pressure who do not reduce their blood pressure by participating in small groups.
Study NCT05220332 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Money Smart
Description: The Money Smart program for adults was developed by the Federal Deposit Insurance Corporation (FDIC). It consists of training modules that cover basic financial topics including deposit and credit services offered by financial institutions, how to obtain and use credit effectively, and the basics of building or repairing credit. This group-based program will be delivered in 14 sessions over 6 months and will be led by a trained instructor.
Study NCT05334069 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT05334069 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of tissue and blood samples
Study NCT06141538 — intervention group
Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.
Study NCT04450368 — intervention group
Intervention type: DEVICE
Intervention: Sylvee
Description: The investigators have developed a small sensor that has the same characteristics as a combined hearing aid used for Tinnitus. It has a noise generator intended to transmit white noise (2 - 20 KHz) and a microphone similar to those used in hearing aids to provide sound amplification. Our sensor is substantially equivalent to legally FDA approved marketed devices that can be used for several hours per day. Although it will introduce new indications for use (lung resonance capture), it has the same technological characteristics and will not introduce new hazards or safety risks. Several sound-based devices are already in use for clearing mucus from the lungs by generating and delivering low frequency sound that vibrates the airways and lung secretions, causing them to thin and become expelled. The devices are placed on the patient's chest for up to 3-4 hours in COPD, cystic fibrosis (CF) and other lung diseases.
Study NCT05056844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodinated Contrast Agent
Description: Given iodine-based contrast agent IV
Study NCT05601817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vita
Description: Vita is developed by this study team based on Attention Restoration Theory. The Vita intervention involves viewing 360 degree nature pictures on a virtual reality headset.
Study NCT05601817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Com
Description: Com intervention uses BrainHQ from PositScience that was developed based on the brain neuroplasticity. The com intervention involves doing game-like training on a iPad.
Study NCT05601817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vita+Com
Description: Vita+Com intervention is a combination of both Vita and Com interventions. Participants will be asked to complete Vita first and then Com intervention.
Study NCT05056844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04316546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7075 (miransertib)
Description: MK-7075 (miransertib) is a small molecule developed by ArQule Inc., a wholly owned subsidiary of Merck Sharp \&amp; Dohme (Merck), that effectively inhibits AKT. Proteus syndrome is caused by mosaic activating mutations in AKT1. This is a Phase 2 trial investigating the efficacy of miransertib as a treatment for adult and pediatric patients with Proteus syndrome.
Study NCT06073080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Nutrition During Recovery
Description: Dietary Protein Nutrition Distribution
Study NCT06073080 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein Nutrition During Recovery
Description: Dietary Protein Nutrition Distribution
Study NCT05798026 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.
Study NCT05798026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU103
Description: EU103 will be administered via intravenous infusion.
Study NCT05134857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
Study NCT05134857 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The PLO will be supplied at the same schedule and in the same manner (TAD device) as the ZON.
Study NCT06273293 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fractional Flow Reserve
Description: Agreement measurements between the different post-ICP functional values (cFFR+NTG and FFR) will be performed at the end of the intervention on the treated vessels. The study protocol consists of 4 sequential steps (separated by at least 30 sec):~1. Determination of FFR with contrast and NTG: cFFR +NTG will be calculated with the lowest ratio after the infusion of 0.2 mg bolus of intracoronary NTG and pushed with contrast.~2. Determination of distal pressure between basal aortic pressure: The Pd/Pa will be obtained after about 30-60 seconds of the NTG bolus in step 1.~3. Determination of the diastolic dPR index: the average value (2-3 determinations).~4. Determination of fractional flow reserve with adenosine: The FFR will be obtained after continuous peripheral venous infusion with adenosine or with intracoronary boluses according to the protocol of each center.
Study NCT04838613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]CTT1057
Description: Single intravenous dose of approximately 370 Mega-Becquerel (MBq) and subsequent PET/CT scan
Study NCT04838613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11
Description: Single intravenous dose of approximately 150 MBq and subsequent PET/CT scan
Study NCT06431490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB2102 for injection
Description: TQB2102 for injection is a HER2 dual-antibody-drug Conjugate (ADC)
Study NCT04762849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic one anastomosis gastric bypass
Description: Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.
Study NCT04762849 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic one anastomosis gastric bypass
Description: Laparoscopic one anastomosis gastric bypass include the creation of gastric pouch; a jejunal loop measure about 200 cm from the ligament of Treitz and anastomosed to the gastric pouch. For the creation of a gastric pouch and gastroenterostomy use a linear stapler.
Study NCT04762849 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A shape-memory ring for adjustable gastric banding
Description: A shape-memory ring (SMR) use for adjustable gastric banding. SMR is placed around the gastric pouch above the gastro-entero-anastomosis.
Study NCT04163510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Parent/Child Reading Program
Description: A 9-week parent/child reading program will help parents to identify strategies to establish literacy routines with their children, and to engage with them in enjoyable literacy activities that promote skill building while reducing negative feelings associated with reading. Three large-group sessions will be held in a central location, to build community and rapport among researchers and participants. Six individual sessions will take place in the participants' homes, to customize reading strategies and routines to each family's home setting and personal interests. Intervention sessions will be held once per week for 60-90 minute sessions.
Study NCT05368987 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS)
Description: Research subjects will undergo non-invasive TMS, with a frequency of 20Hz and intensity of 120% of their resting motor threshold (rMT) at varying time points and locations.
Study NCT05052047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brisk Walking Group
Description: Brisk Walk: 20 min/day (The researchers found, for most people, brisk walking could be defined as moving at a pace of 2.7 miles per hour or 100 steps per minute for adults under about age 60 or guidelines define brisk walking as occurring when individuals move at a pace that increases their heart rate to about 70% of their heart rate maximum) Patient will also perform breathing exercises as given to Control group, Positioning (lean forward when needed) Percussion coughing when needed
Study NCT05052047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Breathing Exercise Group
Description: Breathing exercises: 20 min/day~Breathing Ex includes:~• Pursed lip breathing: Sit with your back straight, inhale through your nose for 2 seconds. Purse your lips like you rae blowing on hot food and then breath out slowly, take twice as long to exhale as you took to breath in 4-5 times a day~• Diaphragmatic breathing: Lie on your back on a flat surface, knees bent and head supported. Use pillow under knees to support your legs . breathe in slowly through your nose tighten your stomach, letting them fall inward as you exhale through your pursed lips. Practice these exercises 5-10 minutes about 3-4 times a day.~Positioning (lean forward when needed) Percussion coughing when needed